Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Adenovirus encoding human platelet-derived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use.

Chang PC, Cirelli JA, Jin Q, Seol YJ, Sugai JV, D'Silva NJ, Danciu TE, Chandler LA, Sosnowski BA, Giannobile WV.

Hum Gene Ther. 2009 May;20(5):486-96. doi: 10.1089/hum.2008.114.

2.

Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.

Gupta V, Wang W, Sosnowski BA, Hofman FM, Chen TC.

Neurosurg Focus. 2006 Apr 15;20(4):E26.

PMID:
16709032
3.

Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy.

Wang W, Zhu NL, Chua J, Swenson S, Costa FK, Schmitmeier S, Sosnowski BA, Shichinohe T, Kasahara N, Chen TC.

J Neurosurg. 2005 Dec;103(6):1058-66.

PMID:
16381193
4.

Improvement of myocardial contractility in a porcine model of chronic ischemia using a combined transmyocardial revascularization and gene therapy approach.

Horvath KA, Lu CY, Robert E, Pierce GF, Greene R, Sosnowski BA, Doukas J.

J Thorac Cardiovasc Surg. 2005 May;129(5):1071-7.

5.

Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use.

Gu DL, Nguyen T, Gonzalez AM, Printz MA, Pierce GF, Sosnowski BA, Phillips ML, Chandler LA.

Mol Ther. 2004 May;9(5):699-711.

6.

Platelet-derived growth factor B, but not fibroblast growth factor 2, plasmid DNA improves survival of ischemic myocutaneous flaps.

Hijjawi J, Mogford JE, Chandler LA, Cross KJ, Said H, Sosnowski BA, Mustoe TA.

Arch Surg. 2004 Feb;139(2):142-7. Erratum in: Arch Surg. 2004 May;139(5):468.

PMID:
14769570
7.

Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors.

Kleeff J, Fukahi K, Lopez ME, Friess H, Büchler MW, Sosnowski BA, Korc M.

Cancer Gene Ther. 2002 Jun;9(6):522-32.

8.

Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle.

Doukas J, Blease K, Craig D, Ma C, Chandler LA, Sosnowski BA, Pierce GF.

Mol Ther. 2002 May;5(5 Pt 1):517-27.

9.

Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors.

Doukas J, Chandler LA, Gonzalez AM, Gu D, Hoganson DK, Ma C, Nguyen T, Printz MA, Nesbit M, Herlyn M, Crombleholme TM, Aukerman SL, Sosnowski BA, Pierce GF.

Hum Gene Ther. 2001 May 1;12(7):783-98.

PMID:
11339895
10.

FGF2-targeted adenoviral vectors for systemic and local disease.

Sosnowski BA, Gu DL, D'Andrea M, Doukas J, Pierce GF.

Curr Opin Mol Ther. 1999 Oct;1(5):573-9. Review.

PMID:
11249664
11.
12.

FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation.

Chandler LA, Doukas J, Gonzalez AM, Hoganson DK, Gu DL, Ma C, Nesbit M, Crombleholme TM, Herlyn M, Sosnowski BA, Pierce GF.

Mol Ther. 2000 Aug;2(2):153-60.

13.

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

Haisma HJ, Pinedo HM, Rijswijk A, der Meulen-Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR, Curiel DT.

Gene Ther. 1999 Aug;6(8):1469-74.

14.

Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways.

Doukas J, Hoganson DK, Ong M, Ying W, Lacey DL, Baird A, Pierce GF, Sosnowski BA.

FASEB J. 1999 Aug;13(11):1459-66.

PMID:
10428769
15.

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice.

Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A, Aukerman SL, Pierce GF.

Cancer Res. 1999 Jun 1;59(11):2608-14.

16.

Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines.

Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A, Pierce GF.

Int J Cancer. 1999 May 5;81(3):451-8.

17.

Targeted delivery of DNA encoding cytotoxic proteins through high-affinity fibroblast growth factor receptors.

Hoganson DK, Chandler LA, Fleurbaaij GA, Ying W, Black ME, Doukas J, Pierce GF, Baird A, Sosnowski BA.

Hum Gene Ther. 1998 Nov 20;9(17):2565-75.

PMID:
9853523
18.

Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.

Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piché A, Pierce GF, Alvarez RD, Siegal GP, Douglas JT, Curiel DT.

Clin Cancer Res. 1998 Oct;4(10):2455-61.

19.

Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein.

Chandler LA, Sosnowski BA, McDonald JR, Price JE, Aukerman SL, Baird A, Pierce GF, Houston LL.

Int J Cancer. 1998 Sep 25;78(1):106-11.

20.

Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor.

Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, Curiel DT.

Cancer Res. 1997 Apr 15;57(8):1447-51.

21.

Targeting DNA to cells with basic fibroblast growth factor (FGF2).

Sosnowski BA, Gonzalez AM, Chandler LA, Buechler YJ, Pierce GF, Baird A.

J Biol Chem. 1996 Dec 27;271(52):33647-53.

22.

Synthesis and characterization of a homogeneous chemical conjugate between basic fibroblast growth factor and saporin.

Buechler YJ, Sosnowski BA, Victor KD, Parandoosh Z, Bussell SJ, Shen C, Ryder M, Houston LL.

Eur J Biochem. 1995 Dec 15;234(3):706-13.

24.
25.

Molecular genetics of transformer, a genetic switch controlling sexual differentiation in Drosophila.

Belote JM, McKeown M, Boggs RT, Ohkawa R, Sosnowski BA.

Dev Genet. 1989;10(3):143-54.

PMID:
2472240

Supplemental Content

Loading ...
Support Center